Mesenchymal Stem Cells Market 2015-2022 - Global Strategic Business Report 2016 - Development of Regenerative Medicine Accelerates Demand for MSCs - Research and Markets

DUBLIN, Dec 9, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Mesenchymal Stem Cells - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Mesenchymal Stem Cells in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research.

The report profiles 47 companies including many key and niche players such as

• Cell Applications, Inc. (US)
• Celprogen, Inc. (US)
• Cyagen Biosciences, Inc. (US)
• MilliporeSigma (US)
• Genlantis, Inc. (US)
• Thermo Fischer Scientific, Inc. (US)
• Lonza Group (Switzerland)
• Mesoblast Limited (Australia)
• Neuromics (US)
• Orthofix International N.V. (Curacao)
• PromoCell GmbH (Germany)
• R&D Systems, Inc. (US)
• ScienCell Research Laboratories (US)
• Stemcell Technologies Inc (Canada)
• Stemedica Cell Technologies, Inc. (US)
• Trevigen, Inc. (US)
• Vericel Corporation (US)
• Vitro Biopharma (US)
  

Key Topics Covered:

1. MARKET OVERVIEW

• Mesenchymal Stem Cells Market on a Rapid Growth Path
• Current and Future Analysis
• The Present and Future of MSC Therapies
• Select MSC-based Therapeutics
• Mesenchymal Stem Cell Research
• Top 10 Countries Conducting Mesenchymal Stem Cells-based ( MSCs) Clinical Trials 2015
• MSCs are Being Explored for Several New Treatment Possibilities
• Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
• Software Companies Endeavour to Cash in on the Boom

2. MARKET DRIVERS, TRENDS & ISSUES

• Development of Regenerative Medicine Accelerates Demand for MSCs
• Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
• Global Aging Population Statistics
• Opportunity Indicators
• Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells
• Key Disease Statistics
• Opportunity Indicators
• Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
• Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market
• Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
• Adult Stem Cells and Embryonic Stem Cells
• A Comparison
• MSCs versus Embryonic or Induced Pluripotent Stem Cells
• MSC Therapies
• Immune to Ethical Issues Applicable to Embryonic Stem Cells
• MSCs
• A Potential Vehicle for 'Targeted Drug Delivery'
• Stem Cell Based Bone Grafts: Promising Growth Ahead
• Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
• Major Challenges Confronting Mesenchymal Stem Cell Market
• Allogeneic MSCs
• Offering Promise in Immunosuppressive and Tissue Repair Therapy
• Administration Route Determines the Effectiveness of MSCs

3. REVIEW OF SELECT MAJOR STEM CELL VARIANTS